EDIT
NASDAQ
US
Editas Medicine, Inc. - Common Stock
$2.67
▲ +$0.06
(+2.30%)
Vol 1.1M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$200.1M
ROE
-348.6%
Margin
-430.8%
D/E
439.08
Beta
2.15
52W
$1–$5
Wall Street Consensus
20 analysts · Apr 20264
Strong Buy
9
Buy
5
Hold
2
Sell
0
Strong Sell
65.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%
Next Report
May 11, 2026
EPS Estimate: $-0.27
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.27 | — | — |
| Dec 2025 | $-0.26 | $-0.06 | +$0.20 |
| Sep 2025 | $-0.30 | $-0.28 | +$0.02 |
| Jun 2025 | $-0.38 | $-0.63 | $-0.25 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $30.6M | $4.7M | $3.6M | $7.5M | $24.7M |
| Net Income | — | -$45.4M | -$76.1M | -$53.2M | -$25.1M | -$5.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -242.0% | -242.0% | -242.0% | -242.0% | -348.6% | -348.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -1487.8% | -608.9% | -608.9% | -608.9% | -430.8% | -430.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 295.33 | 295.33 | 295.33 | 295.33 | 439.08 | 439.08 |
| Current Ratio | 2.77 | 2.77 | 2.77 | 2.77 | 2.86 | 2.86 |
Key Ratios
ROA (TTM)
-78.6%
P/S (TTM)
4.31
P/B
0.8
EPS (TTM)
$-2.38
CF/Share
$-2.60
Rev Growth 3Y
+8.2%
52W High
$4.54
52W Low
$0.91
$0.91
52-Week Range
$4.54
Financial Health
Free Cash Flow
-$36.4M
Net Debt
-$128.5M
Cash
$146.6M
Total Debt
$18.1M
As of Dec 31, 2025
How does EDIT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
EDIT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4.3
▼
66%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
0.8
▼
68%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
EDIT profitability vs Biotechnology peers
ROE
-348.6%
▼
418%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-430.8%
▼
50%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-78.6%
▼
68%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
EDIT financial health vs Biotechnology peers
D/E ratio
439.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.9
▼
36%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
2.2
▲
122%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
EDIT fundamentals radar
EDIT
Peer median
Industry
EDIT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
EDIT vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
O NEILL GILMORE NEIL
Chief Executive Officer · Mar 03
5394 shs
BURKLY LINDA
Officer · Mar 03
749 shs
PARISON AMY
Chief Financial Officer · Mar 03
474 shs
Last 90 days
Top Holders
Top 5: 25.4%Blackrock Inc.
9.55%
$20.8M
Vanguard Group Inc
8.39%
$18.3M
Renaissance Technologies, L…
3.11%
$6.8M
Geode Capital Management, L…
2.33%
$5.1M
Nuveen, LLC
2.02%
$4.4M
As of Dec 31, 2025
Latest News
The Guardian view on Japan’s hidden century: cheap money, global risk | …
The Guardian · Apr 05
Cenovus Energy Incorporation (CVE) Gets Credit Outlook Upgrade
Yahoo Finance · Apr 04
The Guardian view on the US and Europe: the UK tried to …
The Guardian · Apr 03
Private Credit Bank Run Begins: Blue Owl Gates After Shocking 41% Of …
ZeroHedge · Apr 02
Subprime Crisis 2.0: Will Private Credit Be The Trigger?
ZeroHedge · Mar 29